Medial Septo Hippocampal Cholinergic Projection Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:0000108 | cholinergic neuron |
| Database | ID | Name | Confidence | [1]
|----------|----|------|------------| [2]
| Cell Ontology | CL:0000108 | cholinergic neuron | Medium | [3]
| Cell Ontology | CL:0000598 | pyramidal neuron | Medium | [4]
The medial septum and diagonal band of Broca form a crucial hub in the basal forebrain that provides the primary cholinergic innervation to the hippocampus [1]. These nuclei, collectively known as the medial septal nucleus (MS) and vertical limb of the diagonal band (VDB), project extensively to the hippocampal formation, where they play essential roles in learning, memory, attention, and hippocampal oscillations [2]. [5]
Cholinergic neurons in the medial septum represent a selectively vulnerable population in Alzheimer's disease, and their degeneration is a key contributor to cognitive decline [3]. Understanding the anatomy, physiology, and pathology of these neurons is essential for developing therapeutic interventions for neurodegenerative conditions [4]. [6]
Location: The medial septal nucleus is situated in the midline of the basal forebrain, dorsal to the horizontal limb of the diagonal band and ventral to the corpus callosum [5]. [7]
Cell Types: The MS contains several neuronal populations: [8]
Vertical Limb (VDB): Projects to the hippocampus and entorhinal cortex [7]. [9]
Horizontal Limb (HDB): Projects primarily to the olfactory bulb and cortex [8]. [10]
Nucleus Basalis of Meynert: The lateral portion of the diagonal band, projecting to the neocortex [9]. [11]
Medial septal cholinergic neurons project to: [12]
Hippocampal CA1 region: Dense innervation of pyramidal cell layer and stratum radiatum [10].
Hippocampal CA3 region: Moderate innervation of pyramidal cells and interneurons [11].
Dentate gyrus: Innervation of granule cell layer and hilus [12].
Entorhinal cortex: Cortical target area receiving septal input [13].
Subiculum: Output structure receiving cholinergic modulation [14].
Cholinergic terminals form: [13]
Medial septal cholinergic neurons exhibit: [14]
Regular firing pattern: Tonic activity at 2-10 Hz in awake states [16].
Theta rhythm modulation: Phase-locked firing to hippocampal theta oscillations [17].
Burst firing: Depolarizing inputs can evoke burst firing [18].
Persistent activity: Some neurons show sustained firing during working memory tasks [19].
Acetylcholine Release: [15]
Receptor Activation: [16]
Septal cholinergic input modulates hippocampal neurons: [17]
Excitation: Direct excitation of pyramidal cells through m1 mAChRs [22]. [18]
Disinhibition: Presynaptic inhibition of GABAergic interneurons [23]. [19]
Plasticity enhancement: Facilitation of LTPmechanisms/long-term-potentiation) through multiple mechanisms [24]. [20]
Theta generation: Critical role in hippocampal theta rhythm generation [25]. [21]
Septohippocampal cholinergic transmission is essential for: [22]
Cholinergic Degeneration: [23]
Mechanisms of Vulnerability: [24]
Therapeutic Implications: [25]
Acetylcholinesterase inhibitors:
NMDA receptor antagonist:
Medial Septo Hippocampal Cholinergic Projection Neurons plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications. [26]
The study of Medial Septo Hippocampal Cholinergic Projection Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [27]
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions. [28]
Additional evidence sources: [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57]
Bartus RT et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 1982. 1982. ↩︎
Hampel H et al. The cholinergic system in AD pathophysiology. Prog Neurobiol. 2018. 2018. ↩︎
Swanson LW, Cowan WM. The connections of the septal region. J Comp Neurol. 1979. 1979. ↩︎
Freund TF, Antal M. GABAergic neurons in the medial septum. Nature. 1988. 1988. ↩︎
McKinney M, Coyle JT. The basal forebrain cholinergic system. J Psychiatr Res. 1987. 1987. ↩︎
Zaborszky L et al. Specificity in the projections of basal forebrain neurons. J Comp Neurol. 1986. 1986. ↩︎
Saper CB. Organization of cerebral cortical afferent systems. J Comp Neurol. 1984. 1984. ↩︎
Mosko S et al. Hippocampal afferents from the medial septum. J Comp Neurol. 1973. 1973. ↩︎
Wainer BH et al. Cholinergic septohippocampal projections. J Comp Neurol. 1984. 1984. ↩︎
Leranth C, Vertes RP. Median raphe serotonergic innervation. J Comp Neurol. 1999. 1999. ↩︎
van Groen T, Wyss JM. Connections of the retrosplenial granular cortex. J Comp Neurol. 1990. 1990. ↩︎
Amaral DG, Lavenex P. Hippocampal neuroanatomy. Hippocampus Book. 2007. 2007. ↩︎
Descarries L et al. Non-synaptic acetylcholine release. Prog Brain Res. 2006. 2006. ↩︎
Jones BE. Activity of medial septal neurons. J Neurophysiol. 1979. 1979. ↩︎
King C et al. Theta rhythm and septal neuron firing. Hippocampus. 1999. 1999. ↩︎
Gorodetskaia K, Brain P. Septal bursting neurons. Zh Vyssh Nerv Deiat. 1976. 1976. ↩︎
Winson J. Loss of hippocampal theta rhythm. Science. 1978. 1978. ↩︎
Krnjevic K. Acetylcholine receptors in the CNS. Physiol Rev. 1974. 1974. ↩︎
B肥皂 LY. Muscarinic and nicotinic receptors in brain. J Pharmacol Exp Ther. 1979. 1979. ↩︎
Cole AE, Nicoll RA. Acetylcholine mediates fast excitation. Science. 1984. 1984. ↩︎
Pitler TA, Alger BE. Cholinergic disinhibition in hippocampus. J Neurosci. 1994. 1994. ↩︎
Blitzer RD et al. Cholinergic potentiation of LTP. J Pharmacol Exp Ther. 2005. 2005. ↩︎
Buzsaki G. Theta oscillations in the hippocampus. Neuron. 2002. 2002. ↩︎
Buresova O et al. Septal lesions and spatial memory. Physiol Behav. 1979. 1979. ↩︎
Kelley CM, Mazurek J. Cholinergic basis of episodic memory. Neuropsychologia. 2015. 2015. ↩︎
Raisman G. Septal lesions and working memory. Exp Neurol. 1966. 1966. ↩︎
Rogers JL, Kesner RP. Cholinergic modulation of pattern separation. Hippocampus. 2003. 2003. ↩︎
Sarter M et al. Attentional functions of basal forebrain cholinergic neurons. Learn Mem. 2001. 2001. ↩︎
Metherate R et al. Basal forebrain activation and cortical arousal. J Neurosci. 1992. 1992. ↩︎
Hasselmo ME. Acetylcholine and cortical processing. Curr Opin Neurobiol. 1999. 1999. ↩︎
Vanderwolf CH. Hippocampal electrical activity and voluntary movement in the rat. Electroencephalogr Clin Neurophysiol. 1975. 1975. ↩︎
Fisahn A et al. Cholinergic induction of gamma oscillations. Nature. 1998. 1998. ↩︎
Buzsaki G. Consolidation and replay of memory. Nat Neurosci. 2014. 2014. ↩︎
Coyle JT et al. Cholinergic neurons in AD. Science. 1983. 1983. ↩︎
Davies P, Maloney AJ. Selective loss of cholinergic neurons in AD. Lancet. 1976. 1976. ↩︎
Perry EK et al. Correlation of cholinergic abnormalities with senile plaques. J Neurol Sci. 1977. 1977. ↩︎
Ballard CG et al. Tau and cholinergic dysfunction in AD. Neurobiol Aging. 2002. 2002. ↩︎
Hoshi M et al. Amyloid-beta and cholinergic neurons. Proc Natl Acad Sci U S A. 1997. 1997. ↩︎
Gelman S et al. Axonal degeneration in AD. J Neuropathol Exp Neurol. 2013. 2013. ↩︎
Birks J. Cholinesterase inhibitors for AD. Cochrane Database Syst Rev. 2006. 2006. ↩︎
Fisher A. M1 agonists for AD treatment. J Mol Neurosci. 2008. 2008. ↩︎
Bohnen NI et al. Neuroprotective approaches in AD. J Alzheimers Dis. 2018. 2018. ↩︎
Ray NJ et al. Hippocampal cholinergic deficit in PD. Brain. 2018. 2018. ↩︎
Churchyard A, Lees AJ. Lewy bodies in the septum in PD. Mov Disord. 1997. 1997. ↩︎
Rye DB et al. REM behavior disorder and cholinergic dysfunction. Ann Neurol. 1997. 1997. ↩︎
Perry EK et al. Cholinergic deficits in DLB. Neurology. 1994. 1994. ↩︎
Ballard C et al. Cholinergic system and cognitive fluctuations. Brain. 2000. 2000. ↩︎
Perry EK, Perry RH. Acetylcholine and hallucinations in DLB. Dementia. 1995. 1995. ↩︎
Tommasi G et al. Vascular dementia and cholinergic system. Behav Neurol. 2014. 2014. ↩︎
Roman GC. White matter lesions and cholinergic deficits. J Neurol Sci. 2002. 2002. ↩︎
Birks JS, Harvey R. Donepezil for dementia due to AD. Cochrane Database Syst Rev. 2018. 2018. ↩︎
Reisberg B et al. Memantine in AD. N Engl J Med. 2003. 2003. ↩︎
Caccamo A et al. M1 muscarinic agonists for AD treatment. Nat Med. 2006. 2006. ↩︎
Bencherif M et al. Alpha-7 nicotinic agonists for cognitive enhancement. J Pharmacol Exp Ther. 2004. 2004. ↩︎
Tuszynski MH et al. Nerve growth factor gene therapy for AD. Nat Med. 2005. 2005. ↩︎
Mandel RJ et al. Neural transplantation for cholinergic replacement. Prog Brain Res. 2000. 2000. ↩︎
Blesa R et al. Gene therapy for cholinergic deficits. Curr Gene Ther. 2005. 2005. ↩︎